Author: ["David G. Millar","Rakesh R. Ramjiawan","Kosuke Kawaguchi","Nisha Gupta","Jiang Chen","Songfa Zhang","Takashi Nojiri","William W. Ho","Shuichi Aoki","Keehoon Jung","Ivy Chen","Feng Shi","James M. Heather","Kohei Shigeta","Laura T. Morton","Sean Sepulveda
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Several cancer immunotherapy approaches, such as immune checkpoint blockade and adoptive T-cell therapy, boost T-cell activity against the tumor, but these strategies are not effective in the absence of T cells specific for displayed tumor antigens. Here we outline an immunotherapy in which endogenous T cells specific for a noncancer antigen are retargeted to attack tumors. The approach relies on the use of antibody–peptide epitope conjugates (APECs) to deliver suitable antigens to the tumor surface for presention by HLA-I. To retarget cytomegalovirus (CMV)-specific CD8+ T cells against tumors, we used APECs containing CMV-derived epitopes conjugated to tumor-targeting antibodies via metalloprotease-sensitive linkers. These APECs redirect pre-existing CMV immunity against tumor cells in vitro and in mouse cancer models. In vitro, APECs activated specifically CMV-reactive effector T cells whereas a bispecific T-cell engager activated both effector and regulatory T cells. Our approach may provide an effective alternative in cancers that are not amenable to checkpoint inhibitors or other immunotherapies. Anti-tumor activity of cytomegalovirus (CMV)-specific CD8 T cells is achieved by antibody-mediated delivery of CMV epitopes.
Cite this article
Millar, D.G., Ramjiawan, R.R., Kawaguchi, K. et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 38, 420–425 (2020). https://doi.org/10.1038/s41587-019-0404-8